(Q35579352)

English

Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

scientific article published on November 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. (English)

1 reference

Europe PubMed Central

9 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

10

object named as

Klareskog L

1 reference

Europe PubMed Central

9 August 2017

Gerd-Rüdiger Burmester

5

object named as

Burmester GR

1 reference

Europe PubMed Central

9 August 2017

author name string

Furst DE

1

1 reference

Europe PubMed Central

9 August 2017

Breedveld FC

2

1 reference

Europe PubMed Central

9 August 2017

Kalden JR

3

1 reference

Europe PubMed Central

9 August 2017

Smolen JS

4

1 reference

Europe PubMed Central

9 August 2017

Bijlsma JW

6

1 reference

Europe PubMed Central

9 August 2017

Dougados M

7

1 reference

Europe PubMed Central

9 August 2017

Keystone EC

9

1 reference

Europe PubMed Central

9 August 2017

Mease PJ

11

1 reference

Europe PubMed Central

9 August 2017

language of work or name

0 references

publication date

1 November 2004

1 reference

Europe PubMed Central

9 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

9 August 2017

63 Suppl 2

1 reference

Europe PubMed Central

9 August 2017

ii2-ii12

1 reference

Europe PubMed Central

9 August 2017

Infliximab as a novel therapy for refractory Kawasaki disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Safety of tumour necrosis factor-alpha antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Adalimumab: a review of its use in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Assessment of patients with psoriatic arthritis: a review of currently available measures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Infliximab in active early rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Etanercept therapy in patients with autoimmunity and hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Comparison of the efficacy of the tumour necrosis factor blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Adalimumab (HUMIRA): a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Gastrointestinal side effects in the therapy of rheumatologic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Behçet's disease: a new target for anti-tumour necrosis factor treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Predictors of infection in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Etanercept in the treatment of adult patients with Still's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Infliximab: a review of its use in the management of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Review article: safety of infliximab in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Etanercept: therapeutic use in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Tumor necrosis factor inhibitors for rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Etanercept: a review of its use in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Clinical guidelines: developing guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Cancer morbidity in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Methotrexate and histologic hepatic abnormalities: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

27 July 2018

Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Results from an open-label extension study of etanercept in ankylosing spondylitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Experience with infliximab (anti-TNF monoclonal antibody) as monotherapy for giant cell arteritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Etanercept ameliorates sarcoidosis arthritis and skin disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Treatment with infliximab for a child with Behçet's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Infliximab in the treatment of refractory posterior uveitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Successful treatment of resistant giant cell arteritis with etanercept

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Remission of Behçet's syndrome with TNFalpha blocking treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

RETRACTED: Infliximab in patients with primary Sjögren's syndrome: a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

26 September 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766772

15 November 2018

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of infliximab in resistant psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of myelodysplasia in a patient with active rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mycobacteria tuberculosis peritonitis associated with etanercept therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept as monotherapy in patients with psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizi

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sulfasalazine: a definitively efficient treatment for psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of longstanding active giant cell arteritis with infliximab: report of four cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation

1 reference

https://pubmed.ncbi.nlm.nih.gov/15479866

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ARD.2004.029272

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35579352&oldid=1525095446"